Home > Boards > US Listed > Biotechs >

Enanta Pharmaceuticals (ENTA)

ENTA RSS Feed
Add ENTA Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board: 
Last Post: 5/7/2021 9:50:14 AM - Followers: 72 - Board type: Free - Posts Today: 0
ENTA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ENTA News: Enanta Pharma shows positive effect in early-stage study for hep B therapy 05/06/2021 04:26:52 PM
ENTA News: Enanta Pharma EPS misses by $0.12, misses on revenue 05/06/2021 04:06:14 PM
ENTA News: Current Report Filing (8-k) 05/06/2021 04:05:02 PM
ENTA News: Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2021 with Webcast & Conference... 05/06/2021 04:01:00 PM
ENTA News: Enanta Pharmaceuticals Reports Positive Data from Part 2 of its Phase 1b Study of EDP-514 in Chronic Hepatitis B Virus Patien... 05/06/2021 04:01:00 PM
PostSubject
#1949  Sticky Note ENTA FY2Q21 results—royalty_revenue=$20.1M—3/31/21_cash=$400M: DewDiligence 05/06/21 04:07:21 PM
#1956   ENTA FY2Q21 CC transcript: DewDiligence 05/07/21 09:50:14 AM
#1955   These were nuke-suppressed patients, so their viral-load levels vinmantoo 05/06/21 10:28:26 PM
#1954   Is a 1-log decrease going to be sufficient DewDiligence 05/06/21 06:58:25 PM
#1953   Are you asking about EDP-514? The phase-1b data, vinmantoo 05/06/21 06:45:25 PM
#1952   Are you asking about EDP-514? The phase-1b data, DewDiligence 05/06/21 05:17:18 PM
#1951   Thoughts on the PR and updates ? JK2016 05/06/21 05:08:29 PM
#1950   ENTA reports HBV data_from_ 200mg_and_400mg_cohorts_of EDP-514 phase-1b: DewDiligence 05/06/21 04:16:28 PM
#1949   ENTA FY2Q21 results—royalty_revenue=$20.1M—3/31/21_cash=$400M: DewDiligence 05/06/21 04:07:21 PM
#1948   ABBV maintained its full-year 2021 Mavyret guidance of $2.0B. DewDiligence 04/30/21 09:29:16 AM
#1947   ABBV 1Q21 Mavyret sales=$415M, -14% QoQ: DewDiligence 04/30/21 08:42:00 AM
#1946   ENTA could have a meaningful update on the DewDiligence 04/29/21 03:56:37 PM
#1945   “Today we announced our plans to report our JK2016 04/29/21 03:52:13 PM
#1944   The only difference between the 4/1/21 slide set DewDiligence 04/03/21 04:19:13 PM
#1943   New corporate slide set: DewDiligence 03/31/21 04:20:19 PM
#1942   Any ideas why we fell off a cliff DewDiligence 03/24/21 04:52:58 PM
#1941   Any ideas why we fell off a cliff JK2016 03/24/21 04:40:58 PM
#1940   All-in-one_nasal-swab_Dx_for_ respiratory_viruses_gets_full_FDA_approval— DewDiligence 03/18/21 09:26:13 AM
#1939   Interesting read posted on Seeking Alpha today: JK2016 03/08/21 01:14:31 PM
#1938   ENTA’s_enterprise value_at_the_current_share_ price ($54.78) is ~$870M, based on DewDiligence 02/10/21 02:45:25 PM
#1937   ENTA’s fully-diluted* share count @12/31/20=23.9M—an increase of 0.6M DewDiligence 02/10/21 02:41:30 PM
#1936   ENTA’s pro forma cash @12/31/20=$441.4M—a decrease of $3.9M DewDiligence 02/10/21 02:35:27 PM
#1935   I concur (eom). DewDiligence 02/09/21 12:48:13 PM
#1934   While RVS program is the closest to being vinmantoo 02/09/21 12:27:40 PM
#1933   ENTA FY1Q21 CC transcript: DewDiligence 02/09/21 09:39:53 AM
#1932   ENTA new corporate slide set: DewDiligence 02/08/21 08:03:34 PM
#1931   ENTA FY1Q21* results—royalty_revenue=$31.7M—12/31/20_cash=$405M: DewDiligence 02/08/21 04:13:28 PM
#1930   ABBV’s 2021 Mavyret guidance=$2.0B—(up from actual $1.83B in 2020). DewDiligence 02/03/21 09:37:33 AM
#1929   ABBV 4Q20 Mavyret sales=$481M, +16% QoQ, -23% YoY: DewDiligence 02/03/21 08:23:23 AM
#1928   ENTA upgrades to neutral by JP Morgan. JK2016 01/29/21 05:16:08 PM
#1927   ENTA’s CSO exercised and held ~$700K of stock DewDiligence 01/28/21 06:14:41 PM
#1926   ENTA hires head of business development: DewDiligence 01/26/21 08:52:13 AM
#1925   ENTA new corporate slide set: DewDiligence 01/11/21 09:26:10 AM
#1924   ENTA announces two new programs: 1) an oral DewDiligence 01/08/21 09:02:18 AM
#1923   ENTA hires RSV researcher/clinician as VP, Translation Virology: DewDiligence 01/05/21 08:41:15 AM
#1922   ENTA hires VRTX executive as SVP for new-product strategy: DewDiligence 12/08/20 09:05:54 AM
#1921   ENTA’s enterprise value at the current share price—($42.90)—is DewDiligence 11/28/20 02:41:23 PM
#1920   ENTA’s fully-diluted* share count @9/30/20=23.3M—an increase of 0.6M DewDiligence 11/28/20 02:35:42 PM
#1919   ENTA’s pro forma cash @9/30/20=$445.3M—a decrease of DewDiligence 11/28/20 02:25:09 PM
#1918   ENTA never needs to raise capital, which makes DewDiligence 11/24/20 02:27:38 PM
#1917   Enanta price target lowered to $45 from $52 floblu14 11/24/20 11:14:55 AM
#1916   ENTA FY4Q20 CC transcript: DewDiligence 11/24/20 08:39:19 AM
#1915   ENTA new corporate slide set: DewDiligence 11/23/20 05:34:35 PM
#1914   ENTA FY4Q20* results—royalty_revenue=$23.6M—9/30/20_cash=$419M: DewDiligence 11/23/20 05:17:33 PM
#1913   Thoughts on this PR today? JK2016 11/23/20 04:26:52 PM
#1912   Enanta Pharmaceuticals to Present at Upcoming Investor Conferences floblu14 11/18/20 07:12:54 AM
#1911   Added to my position today. It’s unfathomable rwwine 11/16/20 09:20:39 PM
#1910   Enanta Pharmaceuticals to Host Conference Call on November floblu14 11/16/20 07:18:07 AM
#1909   ENTA investors are currently ascribing negative value to DewDiligence 11/08/20 08:04:10 PM
#1908   ABBV’s Mavyret_2020_guidance=$1.9B—implying ~$560M in 4Q20. (Source: Today’s 3Q2 DewDiligence 10/30/20 09:35:32 AM
#1907   ABBV 3Q20 Mavyret sales=$414M, +10% QoQ, -41% YoY: DewDiligence 10/30/20 09:33:00 AM
PostSubject
Consent Preferences